IL17A and obesity due to melanocortin 4 receptor deficiency: Psoriasis is increasingly recognized as a systemic inflammatory condition associated with elevated risks of cardiovascular disease, metabolic syndrome, obesity, and type 2 diabetes, largely driven by chronic low-grade inflammation mediated through the IL-17/23 axis [43].